CD137 — Drug Target

All drugs that target CD137 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Immune checkpoint inhibitor · Monoclonal antibody

Phase 2 pipeline (3)

• CetuGEX™ · Glycotope GmbH · Immune checkpoint inhibitor · Oncology
  CetuGEX targets the CD137 receptor to stimulate an immune response against cancer cells.
• Adjuvant treatment · GERCOR - Multidisciplinary Oncology Cooperative Group · Immune checkpoint inhibitor · Oncology
  This drug works by enhancing the body's immune response to cancer.
• ESCALATED BEACOPP · Ospedale Santa Croce-Carle Cuneo · Monoclonal antibody · Oncology
  Beacopan is a monoclonal antibody that targets CD137, a member of the tumor necrosis factor receptor superfamily.